Background: Livedoid vasculopathy is an idiopathic, chronic disorder manifested by painful, purpuric macules on the lower extremities that superficially ulcerate, resulting in atrophic, stellate scars with peripheral ...Background: Livedoid vasculopathy is an idiopathic, chronic disorder manifested by painful, purpuric macules on the lower extremities that superficially ulcerate, resulting in atrophic, stellate scars with peripheral telangiectasias and hyperpigmentation. Observations: A 50-year-old man presented with recurrent, painful ulcerations on the medial aspect of his malleoli and calves. The clinical presentation, histologic findings, and results of laboratory evaluation confirmed the diagnosis of livedoid vasculopathy in this case. Despite being refractory to treatment with multiple other medications, the lesions responded dramatically to oral warfarin sodium therapy. Conclusion: Treatment with warfarin may be a beneficial therapy for patients with livedoid vasculopathy.展开更多
目的:研究血管抑制基因治疗对兔耳增生性瘢痕的病理学影响。方法:复制兔耳增生性瘢痕,待创面上皮化后10天瘢痕组织局部多点注射基因重组血管抑制剂Ad-METH1(血管生成抑制因子-1,extracellular protein with metalloprotease and thrombo...目的:研究血管抑制基因治疗对兔耳增生性瘢痕的病理学影响。方法:复制兔耳增生性瘢痕,待创面上皮化后10天瘢痕组织局部多点注射基因重组血管抑制剂Ad-METH1(血管生成抑制因子-1,extracellular protein with metalloprotease and thrombospondin1 domains),30天后观察兔耳瘢痕组织形态、超微结构的变化。结果:Ad-METH1注射后30天,兔耳瘢痕组织学染色显示微血管分布明显减少,超微结构显示内皮细胞肿胀、变性,部分血管丧失功能,成纤维细胞增殖及分泌活性明显降低。结论:Ad-METH1对增生性瘢痕的形成有明确的抑制作用,血管抑制基因治疗有望为增生性瘢痕的防治提供新的方法。展开更多
文摘Background: Livedoid vasculopathy is an idiopathic, chronic disorder manifested by painful, purpuric macules on the lower extremities that superficially ulcerate, resulting in atrophic, stellate scars with peripheral telangiectasias and hyperpigmentation. Observations: A 50-year-old man presented with recurrent, painful ulcerations on the medial aspect of his malleoli and calves. The clinical presentation, histologic findings, and results of laboratory evaluation confirmed the diagnosis of livedoid vasculopathy in this case. Despite being refractory to treatment with multiple other medications, the lesions responded dramatically to oral warfarin sodium therapy. Conclusion: Treatment with warfarin may be a beneficial therapy for patients with livedoid vasculopathy.
文摘目的:研究血管抑制基因治疗对兔耳增生性瘢痕的病理学影响。方法:复制兔耳增生性瘢痕,待创面上皮化后10天瘢痕组织局部多点注射基因重组血管抑制剂Ad-METH1(血管生成抑制因子-1,extracellular protein with metalloprotease and thrombospondin1 domains),30天后观察兔耳瘢痕组织形态、超微结构的变化。结果:Ad-METH1注射后30天,兔耳瘢痕组织学染色显示微血管分布明显减少,超微结构显示内皮细胞肿胀、变性,部分血管丧失功能,成纤维细胞增殖及分泌活性明显降低。结论:Ad-METH1对增生性瘢痕的形成有明确的抑制作用,血管抑制基因治疗有望为增生性瘢痕的防治提供新的方法。
